Catalyst Clinical Research
Catalyst Clinical Research was a privately held oncology-focused contract research organization providing early-phase clinical trial services, cell and gene therapy research, and rare disease studies to pharmaceutical and biotechnology companies through FSP and full-service models.
- Company typePrivate
- Founded2013
- HeadquartersWilmington, United States
- Headcount1,001–5,000
- GTM typeB2B
- OfferingServices
What Catalyst Clinical Research does
Catalyst Clinical Research was a specialized oncology contract research organization (CRO) founded in 2013 and headquartered in Wilmington, North Carolina. The company provided clinical development services to pharmaceutical and biotechnology companies, focused on early-phase oncology trials, cell and gene therapy development, and rare disease research. Prior to its February 2026 acquisition by Worldwide Clinical Trials, Catalyst was privately held and backed by private equity firm QHP Capital. Customers were enterprise pharmaceutical and biotechnology companies conducting oncology drug development programs.
Catalyst Clinical Research firmographics
Firmographics- Name
- Catalyst Clinical Research
- Website
- https://catalystcr.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Acquired
- Headcount range
- 1,001–5,000 employees
- Short description
- Catalyst Clinical Research was a privately held oncology-focused contract research organization providing early-phase clinical trial services, cell and gene therapy research, and rare disease studies to pharmaceutical and biotechnology companies through FSP and full-service models.
- Ownership category
- akta.pro rank
Catalyst Clinical Research industry classification
Industry- Product category
- Contract Research Organization (Clinical Research Services)
- NAICS
- Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)
- akta.pro secondary industries
- Clinical CROs (Phase I–IV) (HLAGAAAA), Clinical Operations & Monitoring FSP (CRA/CTM/Start-up) (HLAGAOAA), Patient Recruitment, Site Feasibility & Trial Enablement CROs (HLAGAAAI)
Keywords
Where Catalyst Clinical Research is headquartered
LocationHeadquarters
- HQ city
- Wilmington
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Catalyst Clinical Research business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Clinical Research Services: Catalyst generated revenue by providing contract clinical research services to pharmaceutical and biotechnology companies conducting oncology clinical trials. Services included early-phase oncology studies, clinical operations, biometrics, and functional service provision under fee-for-service and FSP arrangements.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom clinical research service engagements |
Go-to-market motion2 records
Distribution channels1 record
Marketing channels1 record
Catalyst Clinical Research product offering
Product offeringCore offering
Catalyst Clinical Research is a specialized oncology contract research organization (CRO) that delivers clinical trial services to pharmaceutical and biotechnology companies. Core offerings include early-phase oncology studies, full-service oncology clinical research, cell and gene therapy programs, rare disease research, biometrics, and a flexible Functional Service Provider (FSP) engagement model enabling clients to scale clinical operations support on a customized basis.
Product overview
Catalyst Clinical Research operated as a specialized oncology contract research organization (CRO) offering a platform of clinical development services. The core offerings included early-phase oncology expertise and a Functional Service Provider (FSP) model, supplemented by acquired capabilities from Genpro Research (global operations in US, India, Ireland) and Aptus Clinical (European expertise in oncology, cell and gene therapies, and rare diseases). The company engaged in more than 100 active oncology studies at the time of its acquisition by Worldwide Clinical Trials in Q1 2026.
Differentiator
Problem solved
Functional benefit
Products and services
- Early Phase Oncology Services Specialized contract research services for early-phase oncology clinical trials, including Phase I and proof-of-concept studies, delivered to pharmaceutical and biotechnology sponsors developing oncology therapeutics.
- Functional Service Provider (FSP) Model Flexible FSP engagement model allowing pharmaceutical and biotechnology sponsors to access specialized clinical research functions (biometrics, clinical operations, data management, etc.) on a scalable, customizable basis.
- Oncology Clinical Research Full-service oncology clinical trial management covering multiple cancer types including solid tumors and hematologic malignancies, provided to pharmaceutical and biotechnology sponsors.
- Cell and Gene Therapy Services Specialized clinical research services for cell and gene therapy development programs, delivered to pharmaceutical and biotechnology sponsors in oncology and rare disease indications.
- Rare Disease Research Clinical research services focused on rare oncology indications and rare diseases, delivered to pharmaceutical and biotechnology sponsors.
Quantifiable outcome
- More than 100 active oncology studies at time of Aptus acquisition (2022)
- +1 more outcomes
Companies that use Catalyst Clinical Research
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles2 records
Catalyst Clinical Research technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Catalyst Clinical Research partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- Worldwide Clinical TrialscoreWorldwide Clinical Trials completed acquisition of Catalyst Clinical Research in February 2026. The transaction integrated Catalyst's early-phase oncology expertise and FSP model with Worldwide's late-phase development and CNS capabilities, creating a combined organization operating across more than 70 countries with approximately 4,400 employees.
- Genpro ResearchcoreCatalyst Clinical Research acquired Genpro Research, a global clinical research organization with operations in the US, India, and Ireland. This acquisition expanded Catalyst's global footprint and operational capabilities.
- Aptus ClinicalcoreCatalyst acquired Aptus Clinical to expand its presence in Europe and enhance clinical research services in oncology, cell and gene therapies, and rare diseases. The combined entity aimed to accelerate growth in the US and Europe.
Scale indicators3 records
Recent moves5 records
Expansion highlights5 records
Catalyst Clinical Research competitors and assessment
Company assessmentDirect peers
- Medpace: Mid-to-large global CRO with a strong oncology franchise and therapeutic-area-aligned operating model; competes head-to-head with Catalyst for oncology clinical trial work from pharma and biotech sponsors.
- Worldwide Clinical Trials: Global CRO with deep oncology, neuroscience, and rare disease expertise that acquired Catalyst in February 2026; the acquirer and now parent, operating the combined platform.
- Ergomed: Specialty CRO with a strong oncology and rare disease focus, including a dedicated FSP offering; competes with Catalyst for early-phase oncology and rare-disease trial work.
Emerging players
- Translational Drug Development (TD2): Specialty oncology CRO focused on early-phase and translational drug development; competes with Catalyst for early-phase oncology studies from biotech sponsors.
- Precision for Medicine: Specialty CRO focused on oncology and rare disease clinical trials with biomarker and laboratory services; directly overlaps with Catalyst's oncology and rare-disease offerings.
Broad incumbents
- Novella Clinical (IQVIA): Oncology-focused CRO that was acquired by IQVIA; continues to compete in the oncology specialty space as part of IQVIA's broader clinical services portfolio.
- ICON plc: Top-tier global CRO offering full-service clinical development including oncology; competes with Catalyst for large pharma oncology programs.
- IQVIA: Largest global CRO with extensive oncology capabilities; competes with Catalyst across the full oncology trial lifecycle, especially for large pharma mega-programs.
- Parexel: Global CRO with established oncology and rare disease capabilities; competes with Catalyst for full-service and FSP oncology engagements with pharma and biotech.
- Labcorp Drug Development (formerly Covance): Major global CRO with broad oncology and central laboratory capabilities; competes with Catalyst in oncology clinical trial execution and biomarker testing.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights5 records
Customer concentration
Catalyst Clinical Research social profiles
Digital presenceCatalyst Clinical Research financial estimates
Financial estimateRevenue estimate
Valuation estimate
Catalyst Clinical Research leadership team
Management profileNumber of profiles
Profiles2 records
Catalyst Clinical Research subsidiaries and ownership
Company hierarchySubsidiaries2 records
Catalyst Clinical Research funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Catalyst Clinical Research M&A and investment
M&A and investmentM&A4 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Catalyst Clinical Research
What does Catalyst Clinical Research do?
Catalyst Clinical Research is a specialized oncology contract research organization (CRO) that delivers clinical trial services to pharmaceutical and biotechnology companies. Core offerings include early-phase oncology studies, full-service oncology clinical research, cell and gene therapy programs, rare disease research, biometrics, and a flexible Functional Service Provider (FSP) engagement model enabling clients to scale clinical operations support on a customized basis.
Is Catalyst Clinical Research a public or private company?
Catalyst Clinical Research is a private company. It is classified as corporate owned and is currently acquired.
When was Catalyst Clinical Research founded?
Catalyst Clinical Research was founded in 2013. It employs 1,001 to 5,000 people.
Where is Catalyst Clinical Research based?
Catalyst Clinical Research is headquartered in Wilmington, United States, in the North America region.
How does Catalyst Clinical Research make money?
One revenue line is on record: clinical Research Services.
Who are Catalyst Clinical Research's main competitors?
Direct peers on record are Medpace, Worldwide Clinical Trials and Ergomed. Emerging players are Translational Drug Development (TD2) and Precision for Medicine. Broad incumbents are Novella Clinical (IQVIA), ICON plc, IQVIA, Parexel and Labcorp Drug Development (formerly Covance).
Does Catalyst Clinical Research have an API?
No public API is recorded for Catalyst Clinical Research.
What industry is Catalyst Clinical Research in?
Catalyst Clinical Research's product category is Contract Research Organization (Clinical Research Services). Its primary akta.pro industry code is HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease), with a secondary code of HLAGAAAA, Clinical CROs (Phase I–IV). Its NAICS code is 5417 and its SIC code is 8731.